Masafumi Ikeda

E7386 Enhances Lenvatinib's Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research · 1 december 2025

Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclita...

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025-11

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as eerstelijns treatment for unresectable hepatocellular car...

Lancet (London, England) · 24 mei 2025

Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non...

Lancet (London, England) · 18 januari 2025

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo bij HCC: LEAP-002 fase III

The Lancet. Oncology · 2023-12

mFOLFIRINOX versus gemcitabine-nab-paclitaxel bij lokaal gevorderd pancreascarcinoom: fase II

European journal of cancer (Oxford, England : 1990) · 2023-03

Etoposide-cisplatine versus irinotecan-cisplatine bij gevorderd SCLC

JAMA oncology · 1 oktober 2022

S-IROX bij gevorderd pancreascarcinoom: fase I/II

European journal of cancer (Oxford, England : 1990) · 2022-10

Prognostische factoren bij HCC met verhoogd AFP onder ramucirumab: REACH-2 analyse

Clinical cancer research : an official journal of the American Association for Cancer Research · 1 juni 2022

Tremelimumab plus durvalumab bij irresectabel HCC: HIMALAYA fase III farmacodynamiek

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 september 2021

Farmacodynamische biomarkers en overleving bij lenvatinib voor HCC

Clinical cancer research : an official journal of the American Association for Cancer Research · 1 september 2021

PROs van atezolizumab-bevacizumab versus sorafenib bij HCC: IMbrave150 analyse

The Lancet. Oncology · 2021-07

Atezolizumab plus bevacizumab bij irresectabel HCC: IMbrave150 fase III

The New England journal of medicine · 14 mei 2020

TAS-118 (S-1 plus leucovorin) versus S-1 bij gemcitabinerefractair pancreascarcinoom

European journal of cancer (Oxford, England : 1990) · 2019-01